ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Participate in Survey to Help our Medical Committee
The ALK Positive Inc. Medical Committee is seeking patient and caregiver input to enhance DDI Manager — an online resource that helps identify potential drug–drug interactions between cancer treatments and other medications. Your feedback can make a real difference in improving this tool for the entire ALK+ community. Participation takes just 10–15 minutes.
-
Takeda Oncology Co-Pay Assistance Progam
As of October 1, 2025, ALUNBRIG® (brigatinib) is now covered at Cigna Healthcare, giving most commercial patients faster access and lower out-of-pocket costs. With this update, about 99% of commercial lives are covered for ALUNBRIG. Learn more about co-pay assistance at takedaoncologycopay.com .
-
Introducing ALK Positive Canada
An interview with Katie Hulan, VP of Advocacy, ALK Positive Canada
-
Sheet Pan Red Pepper and Roast Tomato Soup
If you’re wondering what to do with those end of the season tomatoes on your window sills, or if you simply appreciate what the produce markets offer, this is for you ! Easy as it is delicious, just chop, roast, and blend. Serve with your favorite crusty bread ! By Chef and fellow ALKie Juli…
-
The Colin Barton Spirit of Courage Award
At the 2025 ALK Summit in San Diego, ALK Positive proudly introduced the Colin Barton Spirit of Courage Award—a tribute to the vision, leadership, and tireless dedication of one of our founding members. From helping launch the organization and leading the Medical Committee, to personally funding research and inspiring millions in donations, Colin’s courage has…
-
Clinical Trial Spotlight: Recruiting for Early-Stage ALK-Positive Lung Cancer
For years, people with ALK-positive lung cancer have faced a frustrating reality: while targeted therapies have transformed outcomes for stage IV disease, treatment for earlier stages has lagged behind. For stage I–III cancers—where surgery, chemo, or radiation may be a cure—there’s been little clarity on whether targeted drugs could reduce recurrence and improve survival.
-
Patient Spotlight: Jake Legasse
At just 15 years old, Jake Lagasse was diagnosed with stage IV ALK-positive lung cancer. Thirteen years later, he continues to defy the odds—running marathons, working full-time, and embracing each day while participating in the Nuvalent 655 clinical trial. Jake credits his family, friends, and community for keeping him strong and reminds others facing ALK+…
-
Managing Lorlatinib Together: What Patients and Experts Want You to Know
“Patients can—and should—have a voice in their care. This guide is about giving them the tools to do just that.” — Nancee Pronsati, ALK Positive Inc.
-
Instructions and Call for Patient Participation in The University of Michigan Judith Tam ALK Lung Cancer Research Initiative
Help Advance Personalized ALK+ Research with the University of Michigan The Judith Tam ALK Lung Cancer Research Initiative at the University of Michigan is leading a groundbreaking effort to better understand and treat ALK-positive non-small cell lung cancer (NSCLC). By collecting patient samples—blood, tumor tissue, and malignant fluid—over time, researchers are building a deep, individualized…
-
Introducing Oncogene Cancer Research
An interview with Co-founder & Chair, Yvonne Diaz (also a Board Member of ALK Positive Inc) This month, we speak with Yvonne Diaz, a Board Member of ALK Positive Inc and the co-founder of Oncogene Cancer Research, a UK-based patient organization dedicated to empowering patients, championing advocacy, and accelerating clinical research.
-
-
Clinical Trial Spotlight: Tumor-Infiltrating Lymphocyte Therapy for ALK-Positive NSCLC at Moffitt Cancer Center
For ALK-positive patients who have progressed after targeted therapy, a new clinical trial at Moffitt Cancer Center offers renewed hope. This Phase 1 study explores an enhanced form of Tumor-Infiltrating Lymphocyte (TIL) therapy—empowering a patient’s own immune cells with a genetic boost to better recognize and fight cancer. With its focus on ALK, EGFR, ROS1,…